Provista Diagnostics to Present at Rodman & Renshaw Annual Global Investment Conference

NEW YORK, Sept. 9, 2014 (GLOBE NEWSWIRE) -- Provista Diagnostics, Inc., a privately-held molecular diagnostics company focused on developing and commercializing proprietary blood-based diagnostic, prognostic and monitoring tests for cancers affecting women, today announces that David Reese, Ph.D., President and Chief Executive Officer, will deliver a corporate overview at the upcoming Rodman & Renshaw Annual Global Investment Conference taking place September 8 - 10, 2014 at the New York Palace Hotel.

Dr. Reese will be presenting on September 10, 2014 at 2:30 p.m. Eastern time.

About Provista Diagnostics, Inc.

Provista Diagnostics, Inc. is a privately held molecular diagnostics company focused on developing and commercializing proprietary, blood-based diagnostic, prognostic and monitoring tests for cancers affecting women, including breast, ovarian, and other gynecologic malignancies. Tests are performed in Provista's high complexity clinical laboratory, which is licensed in 49 states, is certified by the Centers for Medicare & Medicaid Services (CMS) to be compliant with the Clinical Laboratory Improvement Amendments (CLIA) and is accredited by the College of American Pathologists (CAP). Additional information about Provista Diagnostics is available at Provistadx.com. Information about Provista Diagnostics' clinical trials is available at www.clinicaltrials.gov.

Safe Harbor Statement

Statements contained in this communication not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Provista's actual results may differ materially due to a number of factors, many of which are beyond Provista's ability to predict or control, including among others, viability and effectiveness of our sales approach and overall marketing strategies, the outcome of development or regulatory review of our products, commercial success or acceptance by the medical community, competitive responses, our ability to raise additional capital, and the ability to successfully file a registration statement with the SEC. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. Provista operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Provista undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.

CONTACT: David R. Holmes Provista Diagnostics, Inc. HolmesD@ProvistaDx.com (212) 202-3170Source:Provista Diagnostics